CLOU064C12301 - A randomized double-blind double-dummy parallel-group study comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis followed by extended treatment with open-label remibrutinib
Brief description of study
The main purpose of the study is to find out if patients treated with remibrutinib may experience fewer multiple sclerosis (MS) relapses (also called clinical attacks, exacerbations or flare ups) than patients treated with teriflunomide (also known as Aubagio®). Teriflunomide is an approved medication for the treatment of relapsing MS.
Clinical Study Identifier: s23-01228
ClinicalTrials.gov Identifier: NCT05147220
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
